PreveCeutical Signs Research and Option Agreement with UniQuest Pty Limited for Development of Non-Addictive Analgesic Peptides
PreveCeutical Medical Inc. (the “Company” or “PreveCeutical”) (CSE: PREV, OTCQB: PRVCF, FSE: 18H), announces that, further to its news release dated August 8, 2017, it has entered into a research...Read MorePreveCeutical signs Research and Option Agreement with UniQuest Pty Limited for Developing Dual-Gene Therapy Treatment for Diabetes and Obesity
PreveCeutical Medical Inc. (the “Company” or “PreveCeutical”) (CSE: PREV) announces, further to its news release dated April 13, 2017, that it has entered into a research and option agreement through an agreement...Read MorePreveCeutical Signs Research and Development Agreement with UniQuest Pty Limited for Extraction, Formulation and Ex Vivo Evaluation of Cannabinoids (“CBD”s) for Delivery via Sol-Gels.
PreveCeutical Medical Inc. (“PMI”) a health and wellness company focused on utilising nature and science for the benefit of health-conscious consumers, is pleased to announce that it has signed a research...Read MorePreveCeutical Signs Research and Development Agreement with UniQuest Pty Limited for Development of Caribbean Blue Scorpion Venom-Derived Natural & Synthetic Peptides
PreveCeutical Medical Inc. (“PMI”) a health and wellness company focused on utilizing nature and science for the benefit of health-conscious consumers, is pleased to announce that it signed a research and...Read More